Kei Kishimoto

Company: Selecta Biosciences

Job title: CSO

Seminars:

PANEL DISCUSSION: Where are the Biggest Bottlenecks for Gene Therapy Immunogenicity & Which Approaches are Showing Most Promise (and Feasibility)? 2:30 pm

Actively minimizing immunogenic responses How close are we to redosing? Widening patient eligibility in relation to antibody positivity Exploring innovative vector modificationsRead more

day: Post-Conference Discussion Day - Track A

Effects of ImmTOR Tolerogenic Nanoparticles on Innate, Humoral and Cellular Responses in AAV Gene Therapy and Models of Liver Inflammation 9:30 am

ImmTOR nanoparticles encapsulating rapamycin have been shown to mitigate the antibody response to AAV and enable redosing ImmTOR also inhibits hepatic NFkappaB activation, a master regulator of inflammation, in response to high doses of AAV ImmTOR enhances the tolerogenic environment of the liver and is protective in mouse models of liver inflammationRead more

day: Post-Conference Discussion Day - Track A